Emily Rosenorn-Lanng

Emily Rosenorn-Lanng

Auto-generated profile, based on publicly available information

Emily Rosenorn-Lanng

National Centre for Post-Qualifying Social Work

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2023 in Interactive Learning Environments
Verified
Journal Article
Open access
JHJane Henriksen-Bulmer
Jane Henriksen-Bulmer
EREmily Rosenorn-Lanng
Emily Rosenorn-Lanng
SCStevie Corbin-Clarke
Stevie Corbin-Clarke
SWSamuel Ware
Samuel Ware
DMDavide Melacca
Davide Melacca
LFLee-Ann Fenge
Lee-Ann Fenge

3 July 2021
Verified
Book Chapter
Closed access
CPColin Pritchard
Colin Pritchard
BBBrian Birch
Brian Birch
THTamish Hickish
Tamish Hickish
EREmily Rosenorn-Lanng
Emily Rosenorn-Lanng
Introduction: Britain’s cancer survival results have been criticised as being significantly higher than twenty Major Developed Countries (MDC). Hence this comparison of current UK Total Age-Standardised-Death-Rates (ASDR), female Breast and Prostate cancer mortality rates with twenty (MDC) between1989 to 2015 to determine any significant change. Method: WHO data ASDR per million (pm) for Total, Breast and Prostate cancer mortality rates examined for the years 1989-91 to 2013-15. Confidence Intervals (+/- 95%) are used to determine any significant differences between the UK and other country’s outcomes over the period. Chi square tests for each nation’s Breast and Prostate mortality. Results: Every country’s Total ASDR, Breast and Prostate cancer mortality fell except Greece and Japan. Total ASDR Male cancer mortality rates ranged from Portugal 1653pm to Sweden 1232pm. UK at 1475pm were 10th but had been 6th highest. Total ASDR Female rates went from Denmark’s 1176pm to Japan’s 740pm, the UK 1092pm now 5th but previously had been second highest. No country’s Total rates fell significantly more than Britain’s who had significantly bigger reductions than four other countries for both sexes. Breast mortality ranged from Ireland’s 206pm to Japan’s 99pm, UK rates fell significantly more than five countries. Whilst Breast mortality fell in every country Norway and UK had significantly bigger reductions in Breast than Prostate deaths, conversely France’s Prostate rates fell more than Breast mortality. Prostate mortality went from Norway 213pm Japan’s 60pm, the UK 167pm and five countries had greater reductions than Britain. Conclusions: Results reflect well on UK services for Total and Breast cancers, showing the NHS achieving more with proportionately less as Britain spends less on health than most MDC. The need how to improve UK prostate results are briefly discussed, such as a public information campaign to match the successful Breast cancer aware programme of the 1990’s.